MetaCap

Carlsmed Inc. (CARL)

NASDAQ: CARLHealth CareMedical/Dental InstrumentsUSD

17.42+0.20 (+1.16%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CARL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$477.38M
EPS (TTM)
-$1.13
52-week range
8.50 – 19.15
Day range
16.91 – 18.25
Volume / Avg
261.68K / 112.80K
Beta
—

52-week range

$8.50$19.15

CARL stock today

On Nov 20, CARL ended the session at $17.42, adding $0.20 (1.16%), versus the S&P 500's 3.70% decline. Volume was 2.3x the average at 261.68K shares, a sign of unusually heavy trading. At this level, CARL sits near the top of its 52-week range of $8.50 to $19.15: 9.0% below the high, set on Nov 11, 2026 and 104.9% above the low.

CARL is up 41.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 39.5%. Carlsmed has posted a net loss over the last twelve months (EPS of -$1.13), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Carlsmed

Company profile

Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants.

Industry
Medical/Dental Instruments
CEO
Mr. Michael John Cordonnier
Headquarters
Carlsbad, CA
Employees
127
IPO year
2025

Financial highlights

Full financials

In fiscal 2025, Carlsmed generated $50.5 million in revenue, up 85.9% from fiscal 2024. Carlsmed reported a net loss of $29.6 million, compared with a loss of $24.3 million a year earlier. Gross margin was 75.3% (up from 73.8%) and operating margin -60.5%.

Carlsmed annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024
Revenue$50.51M$27.16M
Growth+85.94%—
Net income$-29.63M$-24.26M
EPS (diluted)$-2.12$-6.11

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$22.00+26.29%

  • Strong buy 2
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $18.00High $26.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.40 vs $-0.42
Surprise
+4.76%

CARL news

All CARL news

Carlsmed peers

Health Care sector
CARL peer companies
CompanyPrice% ChgMarket capCompare
ANGOAngioDynamics Inc.10.81+0.46%$454.61Mvs CARL
RCELAvita Medical Inc.15.62-2.31%$494.96Mvs CARL
MDXGMiMedx Group Inc3.05-1.93%$445.07Mvs CARL
SENSSenseonics Holdings Inc.8.02-9.94%$439.34Mvs CARL
SIShoulder Innovations Inc.20.15-0.79%$421.58Mvs CARL
MOBIMobia Medical Inc.11.85-0.08%$394.50Mvs CARL
SGHTSight Sciences Inc.10.18-4.14%$565.79Mvs CARL
CERSCerus Corporation1.85-2.63%$373.62Mvs CARL

Indexes, lists and sector

Carlsmed stock FAQ

What is Carlsmed's stock price today?

CARL last traded at $17.42 as of Nov 20, 4:00 PM EST, up 1.16% on the day. Prices are delayed at least 15 minutes.

Who is Carlsmed's CEO?

Mr. Michael John Cordonnier is the chief executive officer of Carlsmed Inc., which has about 127 employees.

What is the CARL 52-week high?

The 52-week high for CARL is $19.15 and the 52-week low is $8.50. The stock is currently 9.0% below its high.

Compare CARL